Zoetis stock has had a difficult run, with the share price down about 59.1% over the past five years, yet the current valuation checks still lean toward the shares looking cheap on several measures.

• Over the past five years, Zoetis has delivered a share price decline of about 59.1%, which puts long term holders firmly in negative territory and raises questions about what the current price already reflects.
• The recent appointment of James Saccaro as Chief Financial Officer and Chief Operating Officer may support confidence in execution and cost discipline, while any setback in turning that governance change into better operational performance could weigh on how much value investors are willing to ascribe to the stock.
• Zoetis scores highly on Simply Wall St's broader valuation checks, with the stock screening as undervalued in 5 of 6 areas, which suggests the current market price is low relative to several fundamental benchmarks.

The issue now is whether Zoetis' depressed share price and strong valuation score add up to a genuine opportunity or simply reflect the risks the market already sees.

Does Zoetis Look Undervalued on Earnings?

The P/E ratio is a useful way to check how much you are paying for each dollar of Zoetis earnings today. Zoetis currently trades on a P/E of about 12.1x, compared with an average of around 15.1x for the wider Pharmaceuticals industry and roughly 28.3x for its closest peers. That places Zoetis at a clear discount to both its sector and more directly comparable companies.

The Fair Ratio for Zoetis is estimated at about 21.5x, which reflects what investors might typically pay for a business with similar characteristics. Against that yardstick, the current 12.1x P/E is significantly lower. The recent appointment of Jay Saccaro as CFO and COO adds a fresh operational focus, yet even with that change the market is still valuing Zoetis below this tailored benchmark and below peers on earnings.

On the P/E multiple, Zoetis stock currently screens as undervalued relative to both the industry and its implied fair ratio.

The Zoetis Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Zoetis' valuation puzzle leaves off and explain what would need to be true about Zoetis' future growth, margins and earnings for the stock to be worth materially more or less than today's price. Each Narrative links a fair value estimate to a specific story about Zoetis' potential catalysts and risks, so you can track over time which storyline seems to be unfolding on the Community page.

One of the top community narratives on Zoetis: 17% undervalued

"There’s hints of genuine value in the position, but I figured there wouldn’t be enough people interested in their single-digit growth..."

Do you think there's more to the story for Zoetis? Head over to our Community to see what others are saying!

The Bottom Line

For Zoetis, the current picture points to a stock that screens as undervalued on earnings multiples, with broader valuation checks also leaning supportive. The market is pricing Zoetis at a discount to peers even after factoring in its current profile, which leaves room for opinion on whether that discount is justified. What matters most from here is whether execution under the refreshed leadership translates into the level of operational performance that would prompt the market to re-rate the P/E, rather than keeping the stock in a value trap bracket.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.